220 related articles for article (PubMed ID: 25245583)
1. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.
Mazloom A; Louis CU; Nuchtern J; Kim E; Russell H; Allen-Rhoades W; Krance R; Paulino AC
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):858-62. PubMed ID: 25245583
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
Naranjo A; Parisi MT; Shulkin BL; London WB; Matthay KK; Kreissman SG; Yanik GA
Pediatr Blood Cancer; 2011 Jul; 56(7):1041-5. PubMed ID: 21328522
[TBL] [Abstract][Full Text] [Related]
4. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.
Polishchuk AL; Li R; Hill-Kayser C; Little A; Hawkins RA; Hamilton J; Lau M; Tran HC; Strahlendorf C; Lemons RS; Weinberg V; Matthay KK; DuBois SG; Marcus KJ; Bagatell R; Haas-Kogan DA
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):839-45. PubMed ID: 24867534
[TBL] [Abstract][Full Text] [Related]
5. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
6. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
Kushner BH; Yeh SD; Kramer K; Larson SM; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1082-6. PubMed ID: 12637474
[TBL] [Abstract][Full Text] [Related]
7. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation.
Li R; Polishchuk A; DuBois S; Hawkins R; Lee SW; Bagatell R; Shusterman S; Hill-Kayser C; Al-Sayegh H; Diller L; Haas-Kogan DA; Matthay KK; London WB; Marcus KJ
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):270-277. PubMed ID: 28068235
[TBL] [Abstract][Full Text] [Related]
8. The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study.
Hamidieh AA; Beiki D; Paragomi P; Fallahi B; Behfar M; Fard-Esfahani A; Hosseini AS; Shamshiri A; Eftekhari M; Ghavamzadeh A
Pediatr Transplant; 2014 Aug; 18(5):510-7. PubMed ID: 24814429
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
Hero B; Hunneman DH; Gahr M; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):220-3. PubMed ID: 11464889
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M; Simon T; Hero B; Schicha H; Berthold F
Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
[TBL] [Abstract][Full Text] [Related]
11. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system.
Suc A; Lumbroso J; Rubie H; Hattchouel JM; Boneu A; Rodary C; Robert A; Hartmann O
Cancer; 1996 Feb; 77(4):805-11. PubMed ID: 8616776
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
13. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
15. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
Matthay KK; Edeline V; Lumbroso J; Tanguy ML; Asselain B; Zucker JM; Valteau-Couanet D; Hartmann O; Michon J
J Clin Oncol; 2003 Jul; 21(13):2486-91. PubMed ID: 12829667
[TBL] [Abstract][Full Text] [Related]
16. Clinical implication of residual MIBG-positive disease in the follow-up of high-risk neuroblastoma treated with tandem high-dose chemotherapy and autologous stem cell transplantation.
Seo ES; Shin M; Lim H; Cho HW; Ju HY; Cho YS; Yoo KH; Koo HH; Lee JW; Sung KW
Pediatr Blood Cancer; 2022 Jul; 69(7):e29502. PubMed ID: 34889513
[TBL] [Abstract][Full Text] [Related]
17. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen.
Mastrangelo S; Rufini V; Ruggiero A; Di Giannatale A; Riccardi R
Pediatr Blood Cancer; 2011 Jul; 56(7):1032-40. PubMed ID: 21344615
[TBL] [Abstract][Full Text] [Related]
19. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.
Haas-Kogan DA; Swift PS; Selch M; Haase GM; Seeger RC; Gerbing RB; Stram DO; Matthay KK
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):28-39. PubMed ID: 12694821
[TBL] [Abstract][Full Text] [Related]
20. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]